51 related articles for article (PubMed ID: 18075516)
1. Kinases meet at TSC.
Wu Y; Zhou BP
Cell Res; 2007 Dec; 17(12):971-3. PubMed ID: 18075516
[No Abstract] [Full Text] [Related]
2. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.
Lee DF; Kuo HP; Chen CT; Hsu JM; Chou CK; Wei Y; Sun HL; Li LY; Ping B; Huang WC; He X; Hung JY; Lai CC; Ding Q; Su JL; Yang JY; Sahin AA; Hortobagyi GN; Tsai FJ; Tsai CH; Hung MC
Cell; 2007 Aug; 130(3):440-55. PubMed ID: 17693255
[TBL] [Abstract][Full Text] [Related]
3. 4-hydroxyestradiol induces anchorage-independent growth of human mammary epithelial cells via activation of IkappaB kinase: potential role of reactive oxygen species.
Park SA; Na HK; Kim EH; Cha YN; Surh YJ
Cancer Res; 2009 Mar; 69(6):2416-24. PubMed ID: 19276383
[TBL] [Abstract][Full Text] [Related]
4. Multiple pathways regulated by the tumor suppressor PP2A in transformation.
Westermarck J; Hahn WC
Trends Mol Med; 2008 Apr; 14(4):152-60. PubMed ID: 18329957
[TBL] [Abstract][Full Text] [Related]
5. Mapping pathways from stress to cancer progression.
Ross K
J Natl Cancer Inst; 2008 Jul; 100(13):914-5, 917. PubMed ID: 18577741
[No Abstract] [Full Text] [Related]
6. Microregulation of plaque neovascularization.
Suárez Y
Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1500-1. PubMed ID: 20631347
[No Abstract] [Full Text] [Related]
7. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
8. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
[TBL] [Abstract][Full Text] [Related]
9. Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes.
Tchaikovski V; Olieslagers S; Böhmer FD; Waltenberger J
Circulation; 2009 Jul; 120(2):150-9. PubMed ID: 19564559
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2-deoxyglucose.
Jiang W; Zhu Z; Thompson HJ
Mol Carcinog; 2008 Aug; 47(8):616-28. PubMed ID: 18247380
[TBL] [Abstract][Full Text] [Related]
12. [Inhibitive effects of mifepristone on growth of breast cancer: experiment with animal model].
Tian XS; Zhou WH; Wu GJ; Sun JZ; Cong MH
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):559-63. PubMed ID: 18649774
[TBL] [Abstract][Full Text] [Related]
13. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
14. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
[TBL] [Abstract][Full Text] [Related]
15. "TOR"rific potential for new human therapies?
McKhann GM
Neurosurgery; 2009 May; 64(5):N14-5. PubMed ID: 19404136
[No Abstract] [Full Text] [Related]
16. Feeding the flame: new research adds to role of inflammation in cancer development.
Brower V
J Natl Cancer Inst; 2005 Feb; 97(4):251-3. PubMed ID: 15713956
[No Abstract] [Full Text] [Related]
17. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
18. GOLPH3 links the Golgi network to mTOR signaling and human cancer.
Abraham RT
Pigment Cell Melanoma Res; 2009 Aug; 22(4):378-9. PubMed ID: 19624311
[No Abstract] [Full Text] [Related]
19. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
[TBL] [Abstract][Full Text] [Related]
20. The TSC-mTOR signaling pathway regulates the innate inflammatory response.
Weichhart T; Costantino G; Poglitsch M; Rosner M; Zeyda M; Stuhlmeier KM; Kolbe T; Stulnig TM; Hörl WH; Hengstschläger M; Müller M; Säemann MD
Immunity; 2008 Oct; 29(4):565-77. PubMed ID: 18848473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
